Prestige Brands Inc. v. Guardian Drug Co.

951 F. Supp. 2d 441, 2013 WL 3199070
CourtDistrict Court, S.D. New York
DecidedApril 18, 2013
DocketNo. 12 CV 7778 (VB)
StatusPublished
Cited by2 cases

This text of 951 F. Supp. 2d 441 (Prestige Brands Inc. v. Guardian Drug Co.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Prestige Brands Inc. v. Guardian Drug Co., 951 F. Supp. 2d 441, 2013 WL 3199070 (S.D.N.Y. 2013).

Opinion

MEMORANDUM DECISION

BRICCETTI, District Judge.

Plaintiff Prestige Brands Inc. (“PBI”) and its affiliate, plaintiff Blacksmith Brands, Inc. (“Blacksmith”), market and sell over-the-counter healthcare products to retailers. Defendant-third-party plaintiff Guardian Drug Company (“Guardian”) is a drug manufacturer that sold certain healthcare products to plaintiffs. In this action, PBI and Blacksmith assert breach of contract and other claims against Guardian arising from three product recalls involving products supplied by Guardian. With respect to the claims arising out of one of the recalled products, Guardian asserts third-party claims against NuSil Technology LLC (“NuSil”), the producer of that product’s active ingredient.

Before the Court is NuSil’s motion to dismiss the third-party complaint (Doc. # 18). For the following reasons, the motion is GRANTED.

The Court has subject matter jurisdiction pursuant to 28 U.S.C. § 1332.

BACKGROUND

For purposes of ruling on NuSil’s motion to dismiss, the Court accepts as true all allegations of the third-party complaint, as forth below.

NuSil manufactures a product known as MED-341, which is used in certain anti-gas medications. Between April 2010 and February 2011, Guardian purchased from NuSil three shipments of MED-341, which Guardian used to manufacture “PediaCare® Infant Gas Relief Drops.”

In the spring of 2011, NuSil discovered that certain lots of MED-341 sold by Nusil had been subject to “possible microbial contamination.” Nusil reported its discovery to the Food and Drug Administration, [444]*444and initiated a voluntary recall. In August 2011, “NuSil requested Guardian to initiate and service on its behalf a recall of several products Guardian manufactured containing the [MED-341] sold by NuSil.” Guardian complied and conducted the recall.

Guardian contends NuSil agreed, “in accordance with industry standards and practices,” to “defend, indemnify and reimburse Guardian for all of the expenses it incurred in connection with the recall and the recall-related expenses that are recoverable by Guardian’s customers.” According to Guardian:

where parties have not otherwise agreed on how recalls are to be handled and conducted, it is understood in the industry and it is an ‘understood industry practice that when the supplier of an active ingredient requests that its customer initiate and service on its behalf a recall of products that contain a potentially harmful active ingredient, the supplier is responsible for all recall costs that its customer[s] incur[ ]. It makes no sense for Guardian to have agreed to initiate and service on NuSil’s behalf the recall, unless NuSil would make Guardian whole for all costs it incurred.

Guardian does not allege it entered into any written agreement with NuSil.

Guardian subsequently requested that NuSil defend and indemnify Guardian for its recall-related expenses. Instead, NuSil refunded to Guardian the full purchase price of the recalled MED-341. Guardian contends it incurred recall-related damages in excess of the amount refunded by NuSil.

Based on the foregoing, Guardian asserts claims against NuSil for (1) breach of contract; (2) breach of the implied covenant of good faith and fair dealing; (3) promissory estoppel; (4) unjust enrichment; and (5) indemnification.

DISCUSSION

I. Legal Standard

“The function of a motion to dismiss is merely to assess the legal feasibility of the complaint, not to assay the weight of the evidence which might be offered in support thereof.” Ryder Energy Distrib. Corp. v. Merrill Lynch Commodities, Inc., 748 F.2d 774, 779 (2d Cir.1984) (internal quotation marks omitted). In deciding a motion to dismiss pursuant to Rule 12(b)(6), the Court evaluates the sufficiency of the complaint under the “two-pronged approach” suggested by the Supreme Court in Ashcroft v. Iqbal, 556 U.S. 662, 679, 129 S.Ct. 1937, 173 L.Ed.2d 868 (2009). First, plaintiffs legal conclusions and “[t]hreadbare recitals of the elements of a cause of action, supported by mere conclusory statements,” are not entitled to the assumption of truth and are thus not sufficient to withstand a motion to dismiss. Id. at 678, 129 S.Ct. 1937; Hayden v. Paterson, 594 F.3d 150, 161 (2d Cir.2010). Second, “[w]hen there are well-pleaded factual allegations, a court should assume their veracity and then determine whether they plausibly give rise to an entitlement to relief.” Ashcroft v. Iqbal, 556 U.S. at 679, 129 S.Ct. 1937.

To survive a Rule 12(b)(6) motion, the allegations in the complaint must meet a standard of “plausibility.” Ashcroft v. Iqbal, 556 U.S. at 678, 129 S.Ct. 1937; Bell Atl. Corp. v. Twombly, 550 U.S. 544, 564, 127 S.Ct. 1955, 167 L.Ed.2d 929 (2007). A claim is facially plausible “when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Ashcroft v. Iqbal, 556 U.S. at 678, 129 S.Ct. 1937. “The plausibility standard is not akin to a ‘probability requirement,’ but it asks for more than a [445]*445sheer possibility that a defendant has acted unlawfully.” Id.

II. Analysis

In support of its motion to dismiss, NuSil has produced purported invoices relating to Guardian’s purchases of MED-341. The invoices list several “Terms & Conditions of Sale,” which include the following provisions relating to Guardian’s ability to maintain a suit against NuSil and where such a suit may be properly brought:

[Guardian]’s exclusive remedy and [NuSilj’s sole responsibility for any claim or cause of action arising under this Agreement is expressly limited to either (1) replacement of all goods shown-to be other than as warranted or (2) refund of the purchase price of all goods shown to be other than as warranted---- In no event may [Guardian] commence any action against [NuSil] with respect to the products after the expiration of eighteen (18) months following the date on which [NuSil] delivers the products.... IN NO EVENT SHALL SELLER BE LIABLE TO PURCHASER, WHETHER IN CONTRACT OR TORT OR FOR BREACH OF STATUTORY DUTY, FOR ANY INCIDENTAL, INDIRECT, CONSEQUENTIAL, OR SPECIAL DAMAGES INCLUDING WITHOUT LIMITATION CLAIMS FOR INDEMNIFICATION, LOST REVENUES AND PROFITS.
Each party further acknowledges that the agreement between the parties has been entered into and shall be performed by [Guardian] in Santa Barbara County, California, and agrees that the exclusive venue for all actions arising under or in connection with these Terms and the order accepted hereby shall be the Superior Court in and for Santa Barbara County, California.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
951 F. Supp. 2d 441, 2013 WL 3199070, Counsel Stack Legal Research, https://law.counselstack.com/opinion/prestige-brands-inc-v-guardian-drug-co-nysd-2013.